Pfizer's Elderly Vaccine Efficacy Drops Slightly After 18 Months, New Clinical Trials Reveal - CDC Advisory Panel Set To Vote Today On Recommended Use Of RSV Shots
Portfolio Pulse from Vandana Singh
Pfizer's vaccine for elderly aged 60 and above showed slightly reduced efficacy after 18 months, according to clinical trial results. The CDC's Advisory Committee on Immunization Practices will vote on the recommendation for using new RSV vaccines from GSK and Pfizer.
June 21, 2023 | 6:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Arexvy vaccine showed efficacy over two full RSV seasons, and the CDC's cost-effectiveness model favored it over Pfizer's vaccine.
GSK's Arexvy vaccine demonstrated efficacy over two RSV seasons, and the CDC's cost-effectiveness model showed it provided more value compared to Pfizer's vaccine. This could lead to a positive recommendation from the CDC panel, potentially increasing demand for GSK's vaccine and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's elderly vaccine efficacy drops slightly after 18 months, potentially affecting the recommendation for its RSV vaccine.
The reduced efficacy of Pfizer's vaccine after 18 months may impact the CDC panel's decision on recommending its RSV vaccine. This could affect the demand for Pfizer's vaccine and potentially lead to a short-term negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100